YESINTEK
As listed in the register: YESINTEK
45 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ustekinumab
- Made by
- Biocon Biologics Canada Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Stelara). It describes the substance, not this exact product.
Ustekinumab is a human IgG1қ monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines.
IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-08
Safety of the active substance
From the US prescribing label for the same active substance (Stelara). It describes the substance, not this exact product.
- STELARA is contraindicated in patients with clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA [see Warnings and Precautions (5.5) ].
- Clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA.
The most frequently observed malignancies other than non-melanoma skin cancer during the clinical trials were: prostate, melanoma, colorectal and breast.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Biocon Biologics Canada Inc |
|---|---|
| Active substance | Ustekinumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 45 mg |
| Form | solution |
| Classification | L04AC05 · Cancer treatments and immune-system medicines |
| Route | subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION · SCHEDULE D |
| Status | Approved |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02569833 |
| DPD drug code | 107204 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
5 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution5 products
45 mg3
45 mg · 3 companies
- Biocon Biologics Canada Inc · this page
- Biocon Biologics Canada Inc
- Biocon Biologics Canada Inc
90 mg2
90 mg · 2 companies
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.